样式: 排序: IF: - GO 导出 标记为已读
-
C3+ and C3− warm autoimmune hemolytic anemias: A comparison of clinical characteristics and treatment outcomes Eur. J. Haematol. (IF 3.1) Pub Date : 2024-04-16 Jordan Nunnelee, Jithma Prasad Abeykoon, Aneel A. Ashrani, Michelle Ann Elliott, C. Christopher Hook, Animesh Pardanani, Rajiv K. Pruthi, Rachelle L. Rouse, Meera Sridharan, Alexandra P. Wolanskyj‐Spinner, Ronald S. Go
-
Post‐transplant‐cyclophosphamide and short‐term Everolimus as graft‐versus‐host‐prophylaxis in patients with relapsed/refractory lymphoma and myeloma—Final results of the phase II OCTET‐EVER trial Eur. J. Haematol. (IF 3.1) Pub Date : 2024-04-15 Tim Richardson, Christof Scheid, Marco Herling, Lukas P. Frenzel, Carmen Herling, Marta Rebecca Cruz Aguilar, Sebastian Theurich, Michael Hallek, Udo Holtick
BackgroundConditioning regimens and the choice of immunosuppression have substantial impact on immune reconstitution after allogeneic hematopoietic stem cell transplantation (aHSCT). The pivotal mechanism to maintain remission is the induction of the graft‐versus‐tumor effect. Relapse as well as graft versus host disease remain common. Classic immunosuppressive strategies implementing calcineurin inhibitors
-
Genetic backgrounds and clinical characteristics of congenital neutropenias in Israel Eur. J. Haematol. (IF 3.1) Pub Date : 2024-04-11 Lital Yeshareem, Joanne Yacobovich, Asaf Lebel, Sharon Noy‐Lotan, Orly Dgany, Tanya Krasnov, Galit Berger Pinto, Nino Oniashvili, Jacques Mardoukh, Bella Bielorai, Ruth Laor, Noa Mandel‐Shorer, Ayelet Ben Barak, Carina Levin, Mahdi Asleh, Hagit Miskin, Shoshana Revel‐Vilk, Dror Levin, Marganit Benish, Tsila Zuckerman, Ofir Wolach, Idit Pazgal, Dafna Brik Simon, Oded Gilad, Asaf David Yanir, Tracie
BackgroundCongenital neutropenias are characterized by severe infections and a high risk of myeloid transformation; the causative genes vary across ethnicities. The Israeli population is characterized by an ethnically diverse population with a high rate of consanguinity.ObjectiveTo evaluate the clinical and genetic spectrum of congenital neutropenias in Israel.MethodsWe included individuals with congenital
-
Measurement of the major ignored burden of multiple myeloma, pernicious anaemia and of other haematological conditions on partners and family members: A cross‐sectional study Eur. J. Haematol. (IF 3.1) Pub Date : 2024-04-05 R. Shah, A. Y. Finlay, F. M. Ali, H. Allen, S. J. Nixon, M. Nixon, K. Otwombe, J. R. Ingram, M. S. Salek
BackgroundHaving a haematological condition can adversely affect the quality of life (QoL) of family members/partners of patients. It is important to measure this often ignored burden in order to implement appropriate supportive interventions.ObjectiveTo measure current impact of haematological conditions on the QoL of family members/partners of patients, using the Family Reported Outcome Measure‐16
-
High dose total marrow irradiation (TMI) does not increase long‐term toxicity of myeloablative fludarabine/busulfan (FluBu4) conditioning regimen in allogeneic hematopoietic stem cell transplantation (HSCT) Eur. J. Haematol. (IF 3.1) Pub Date : 2024-04-03 Lucas Maahs, Pritesh Patel, Matthew Koshy, Karen Sweiss, Zhengjia Chen, Ziqiao Xu, Bulent Aydogan, Damiano Rondelli
ObjectivesBased on a previous phase 1 study, total marrow irradiation (TMI) at 9Gy was added to a myeloablative FluBu4 conditioning regimen in allogeneic hematopoietic stem cell transplantation (HSCT) for myeloid malignancies. Here, we report on the long‐term toxicity of TMI combined with FluBu4 and compare it to patients who received only FluBu4.MethodsWe retrospectively analyzed 38 consecutive patients
-
-
Surgical treatment of invasive fungal infection in pediatric oncology Eur. J. Haematol. (IF 3.1) Pub Date : 2024-04-01 Fati Federica, Zambaiti Elisa, Petris Maria Grazia, Virgone Calogero, Dall' Igna Patrizia, Putti Maria Caterina, De Pieri Marica, Gamba Piergiorgio, Federica DeCorti
BackgroundInvasive fungal disease (IFD) is typically aggressive and related with high mortality in children with a hematological malignancy. The association of medical and surgical treatment may ameliorate the outcome. The aim of this study was to analyze the surgical treatment of fungal infections in pediatric oncological populations.MethodsRetrospective study (2000–2022) of a single‐center experience
-
Pivotal role of dihydroorotate dehydrogenase as a therapeutic target in adult T‐cell leukemia Eur. J. Haematol. (IF 3.1) Pub Date : 2024-04-01 Chie Ishikawa, Naoki Mori
ObjectivesWe aimed to determine the role of dihydroorotate dehydrogenase (DHODH) in pathogenesis of adult T‐cell leukemia (ATL) caused by human T‐cell leukemia virus type 1 (HTLV‐1) and the effects of its inhibition on the de novo pyrimidine biosynthesis pathway.MethodsCell proliferation, viability, cycle, and apoptosis were analyzed using WST‐8 assays, flow cytometry, and Hoechst 33342 staining. To
-
Identification of the molecular etiology in rare congenital hemolytic anemias using next‐generation sequencing with exome‐based copy number variant analysis Eur. J. Haematol. (IF 3.1) Pub Date : 2024-04-01 Esra Isik, Yesim Aydinok, Canan Albayrak, Basak Durmus, Zeynep Karakas, Mehmet Fatih Orhan, Nazan Sarper, Sultan Aydın, Selma Unal, Yesim Oymak, Nihal Karadas, Aysen Turedi, Davut Albayrak, Funda Tayfun, Deniz Tugcu, Serap Karaman, Mahmut Tobu, Ekrem Unal, Alper Ozcan, Sule Unal, Tekin Aksu, Aysegul Unuvar, Mustafa Bilici, Fatih Azik, Yilmaz Ay, Sema Aylan Gelen, Emine Zengin, Esin Albudak, Ibrahim
ObjectivesIn congenital hemolytic anemias (CHA), it is not always possible to determine the specific diagnosis by evaluating clinical findings and conventional laboratory tests. The aim of this study is to evaluate the utility of next‐generation sequencing (NGS) and clinical‐exome‐based copy number variant (CNV) analysis in patients with CHA.MethodsOne hundred and forty‐three CHA cases from 115 unrelated
-
Decreased neutrophil function in newly diagnosed multiple myeloma patients is restored with lenalidomide therapy Eur. J. Haematol. (IF 3.1) Pub Date : 2024-03-30 Sandra Askman, Julia Westerlund, Åsa Pettersson, Thomas Hellmark, Åsa Johansson, Stina Wichert, Markus Hansson
ObjectivesBacterial infections are common and a major cause of morbidity and mortality in multiple myeloma (MM). We have investigated the function of polymorphonuclear leukocyte (PMN), the immune system's first line of defense against bacteria, in peripheral blood (PB) and bone marrow (BM) samples from patients with newly diagnosed MM (NDMM), smoldering MM (SMM), monoclonal gammopathy of undetermined
-
ISTH bleeding assessment tool and platelet function analyzer in children with mild inherited platelet function disorders Eur. J. Haematol. (IF 3.1) Pub Date : 2024-03-29 Dana Alhaj, Nikola Hagedorn, Franziska Cuntz, Madlen Reschke, Joerg Schuldes, Juliane Ruthenberg, Tamam Bakchoul, Andreas Greinacher, Susanne Holzhauer
ObjectivesTo evaluate the diagnostic performance of platelet function analyzer (PFA) and The International Society on Thrombosis and Hemostasis bleeding‐assessment‐tool (ISTH‐BAT) in detecting mild inherited platelet function disorders (IPFDs) in children with suspected bleeding disorders.MethodsProspective single‐center diagnostic study including consecutive patients <18 years with suspected bleeding
-
Ocular adverse events following CAR‐T cell therapy: A pharmacovigilance study and systematic review Eur. J. Haematol. (IF 3.1) Pub Date : 2024-03-29 Connor Frey, Hannah Cherniawsky, Mahyar Etminan
The rise of immuno‐oncology, including the use of chimeric antigen receptor T‐cell (CAR‐T) therapy is bringing in a new wave of cancer treatments, particularly in hematologic malignancies. However, data on their adverse events, particularly of the eye, is under‐reported. To assess the ocular adverse events associated with the six FDA‐approved CAR‐T cell therapies, a disproportionality analysis utilizing
-
Resveratrol and tetrahydroisoquinoline effects on neutrophil sensitivity to NETosis formation in low‐risk essential thrombocythemia patients Eur. J. Haematol. (IF 3.1) Pub Date : 2024-03-28 Fahimeh Shahriyary, Mohammad Reza Amirzargar, Mahshid Vafajoo, Ahmad Kooshari, Ali Basi, Seyed Mohsen Razavi, Behnaz Gharegozlou, Minoo Shahidi
IntroductionRecent studies scrutinize how NETosis (a unique cell death mechanism of neutrophil), impacts thrombosis patients with essential thrombocythemia (ET). This research evaluates the susceptibility of ET neutrophils to form NETs and tests two potential inhibitors, resveratrol (RSV) and tetrahydroisoquinoline (THIQ), in vitro.MethodsPlatelet‐rich plasma from low‐risk ET patients was used, along
-
Reduced clone size upon BTK inhibitor resistance mutations relates to toxicity caused by inherited PLCG2 gain‐of‐function variations Eur. J. Haematol. (IF 3.1) Pub Date : 2024-03-26 C. I. Edvard Smith, Rula Zain
Observations in primary immunodeficiencies frequently impact on other disciplines. We suggest that this may also be the case for the treatment of chronic lymphocytic leukemia (CLL).1, 2 Thus, in CLL and some other B cell malignancies, the targeted treatment using Bruton's tyrosine kinase (BTK) inhibitors (BTKi) has been remarkably successful. However, several forms of resistance mutations have been
-
Chronic kidney disease and outcomes in hospitalized sickle cell disease patients: A National Inpatient Sample analysis Eur. J. Haematol. (IF 3.1) Pub Date : 2024-03-21 Temitope Ajibawo, Oluwatimilehin Okunowo
ObjectivesTo examine the association between chronic kidney disease (CKD) and outcomes in sickle cell disease (SCD) patients.MethodsPatients ≥18 years with SCD in the National Inpatient Sample database between 2016 and 2018 were identified using ICD‐10‐CM diagnosis codes. A 1:1 propensity‐score matched analysis was performed to compare in‐hospital outcomes of patients with and without CKD.ResultsOf
-
Impact of donor NKG2D and MICA gene polymorphism on clinical outcomes of adult and paediatric allogeneic cord blood transplantation for malignant diseases Eur. J. Haematol. (IF 3.1) Pub Date : 2024-03-21 Steven T. Cox, Warren Patterson, Richard Duggleby, Owen J. R. Jones, J. Alejandro Madrigal, Sergi Querol, Francesc Rudilla Salvador, Maria Jose Herrero Mata, Fernanda Volt, Éliane Gluckman, Richard Szydlo, Robert D. Danby, Diana Hernandez
ObjectivesNKG2D is an activating receptor expressed by natural killer (NK) and CD8+ T cells and activation intensity varies by NKG2D expression level or nature of its ligand. An NKG2D gene polymorphism determines high (HNK1) or low (LNK1) expression. MICA is the most polymorphic NKG2D ligand and stronger effector cell activation associates with methionine rather than valine at residue 129. We investigated
-
Transplant versus no transplant in myelodysplastic syndrome and acute myeloid leukemia with TP53 mutation; a referral center experience Eur. J. Haematol. (IF 3.1) Pub Date : 2024-03-21 Kittika Poonsombudlert, Sarah Mott, Benda Miller, Prajwal Dhakal, Anthony Snow, Sarah Hornberg, Ratdanai Yodsuwan, Christopher Strouse, Hira Shaikh, Margarida Magalhaes‐Silverman, Grerk Sutamtewagul
A remarkably high rate of post‐transplant relapse in patients with TP53‐mutated myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) calls to question the utility of allogeneic stem cell transplant (HSCT). We, therefore, performed a retrospective analysis to compare the outcomes between HSCT (N = 38) versus non‐HSCT (N = 45) approaches. Patients in the HSCT cohort were younger (median age 63 vs
-
-
Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11 Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-22 Juehua Gao, Lucas Santana-Santos, Lucy Fu, Emily Alvey, Qing Chen, Kristy Wolniak, Zongjun Xia, Barina Aqil, Amir Behdad, Peng Ji, Madina Sukhanova, Yasmin Abaza, Jessica K. Altman, Yi-Hua Chen, Xinyan Lu
This study assesses the clinical significance of additional cytogenetic abnormalities (ACAs) and/or the deletion of 3′CBFB (3′CBFBdel) resulting in unbalanced CBFB::MYH11 fusion in acute myeloid leukemia (AML) with inv (16)/t(16;16)/CBFB::MYH11.
-
Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-21 Danai Dima, Razan Mansour, James A. Davis, Megan Minchak, Utkarsh Goel, Rawan Atallah, Emerson Logan, Carine Tabak, Aliya Rashid, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi
We conducted a multicenter retrospective study to analyze the safety and efficacy of DPd versus DKd in daratumumab naïve RRMM patients treated in real-world practice.
-
The EASEMENT study: A multicentre, observational, cross‐sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable‐containing or fully oral therapies Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-23 Robert Ayto, Ombretta Annibali, Patricia Biedermann, Montserrat Roset, Emilio Sánchez, Rami Kotb
ObjectiveAs multiple myeloma (MM) therapies advance, understanding patients', caregivers', and physicians' perspectives on, and satisfaction with, available treatment options and their impact on quality of life (QoL), is important.MethodsEASEMENT is a real‐world, observational, cross‐sectional study conducted in 19 sites within the UK, Canada, and Italy using retrospective chart reviews and surveys
-
Value of hemophagocytosis in the diagnosis of hemophagocytic lymphohistiocytosis in critically ill patients Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-18 Peter Nyvlt, Friederike S. Schuster, Jana Ihlow, Patrick Heeren, Claudia Spies, Josephine Hiesgen, Thomas Schenk, Ann-Christin von Brünneck, Jörg Westermann, Frank M. Brunkhorst, Paul La Rosée, Gritta Janka, Cornelia Lachmann, Gunnar Lachmann
Ferritin is an established biomarker in the diagnosis of secondary hemophagocytic lymphohistiocytosis (HLH), which is diagnosed by the HLH-2004 criteria. Among these criteria, detection of hemophagocytosis through invasive procedures may delay early life saving treatment. Our aim was to investigate the value of hemophagocytosis in diagnosing HLH in critically ill patients.
-
Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet PCR Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-19 Jan‐Michel Heger, Yannick d'Hargues, Fanni Kleinert, Julia Mattlener, Jonathan Weiss, Fabian Franzen, Christian Becker, Kerstin Becker, Philipp Gödel, Marcel Schmiel, Jörn Meinel, Ruth Flümann, Florian Simon, H. Christian Reinhardt, Peter Borchmann, Sven Borchmann, Hyatt Balke‐Want, Gero Knittel, Bastian von Tresckow
Although several promising approaches for the treatment of relapsed/refractory diffuse large B‐cell lymphoma (rrDLBCL) have been approved recently, it remains unclear which patients will ultimately achieve long‐term responses. Circulating tumor (ct)DNA sequencing has emerged as a valuable tool to assess minimal residual disease (MRD). Correlations between MRD and outcomes have been shown in previously
-
Recombinant factor IX Fc for the treatment of hemophilia B Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-18 Rolf Ljung, Davide Matino, Amy D. Shapiro
Current hemophilia B treatment guidelines recommend routine prophylaxis with factor IX (FIX) replacement products, tailored to maintain plasma activity at levels that will prevent bleeds. However, plasma FIX activity may not be the primary determinant or best indicator of hemostatic efficacy due to its extravascular distribution. FIX replacement therapy has evolved to include extended half-life (EHL)
-
Featured Cover Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-15 Wolfgang Miesbach, Annette von Drygalski, Clive Smith, Krupa Sivamurthy, Karen Pinachyan, Debbie Bensen-Kennedy, Douglass Drelich, Roshni Kulkarni
-
Development and initial validation of the AL-PROfile patient-reported outcome measure in light chain (AL) amyloidosis Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-13 Anita D'Souza, Aniko Szabo, Idayat Akinola, Muriel Finkel, Kathryn E. Flynn
To evaluate the psychometric properties of the AL-PROfile, a patient-reported outcome measure combining the Patient-Reported Outcomes Measurement Information System (PROMIS)-29, two items from PROMIS Cognitive Function, and select Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) items.
-
Pancreas-related persisting sequelae in ALL survivors with a history of asparaginase-associated pancreatitis: A part of the ALL-STAR study Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-13 Mette Tiedemann Skipper, Niels Birkebæk, Rikke Beck Jensen, Cecilie Utke Rank, Ruta Tuckuviene, Peder Skov Wehner, Trine-Lise Lambine, Arne Hørlyck, Kjeld Schmiegelow, Thomas Leth Frandsen, Liv Andrés-Jensen, Birgitte Klug Albertsen
Asparaginase-associated pancreatitis (AAP) occurs in up to 18% of patients treated for acute lymphoblastic leukemia (ALL); however, long-term sequelae are largely unexplored. We aimed to explore pancreatic sequelae among ALL survivors with and without AAP.
-
Systematic review of hematopoietic stem cell gene therapy approach in thalassemia: Comparative analysis in animal models Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-11 Indira Laksmi Maharani, Muhammad Hafizh Zauhari, Rakean Ahmad Kiansantang, Razzan Satria Wibowo, Rizqi Najla Humaira, Adisti Dwijayanti, Imelda Rosalyn Sianipar
Hematopoietic stem cell (HSC) gene therapy has shown potential as a therapeutic approach for thalassemia in recent years. However, a comparison of the varying gene therapy methods of HSC gene therapy in thalassemia has never been reviewed. This study aims to evaluate the utilization of HSC gene therapy approaches in animal models of thalassemia. A systematic review was conducted in five databases:
-
Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-11 Anke Gerhardt, Steffen Dörfel, Holger Schulz, Rudolf Schlag, Lukas Vornholz, Sonja Nejad-Asgari, Manfred Welslau
To assess treatment adherence, effectiveness and safety outcomes of patients with chronic lymphocytic leukaemia (CLL) receiving ibrutinib in a real-world setting.
-
Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-11 Yue Sun, Gelan Zhu, Hua Zhong
Acute myeloid leukemia (AML) is distinguished by clonal growth of myeloid precursor cells, which impairs normal hematopoiesis. Minimal residual disease (MRD) refers to the residual leukemia cells that persist after chemotherapy. Patients who test positive for MRD have a higher likelihood of experiencing a recurrence, regardless of the specific chemotherapy approach used. Multi-parameter flow cytometry
-
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-09 Alessandro Laganà, Mauro Passucci, Sara Pepe, Emilia Scalzulli, Ida Carmosino, Alessandro Costa, Maria Laura Bisegna, Claudia Ielo, Maurizio Martelli, Massimo Breccia
Myelofibrosis (MF) is a clonal Philadelphia chromosome negative myeloproliferative neoplasm (Ph-MPN). MF is featured by an inflammatory condition that can also drive the progression of disease. Ruxolitinib (ruxo) is the-first-in-class Jak1/2 inhibitor approved for treatment of MF, proved to reduce spleen volume and decrease symptom burden. In various malignancies neutrophil-to-lymphocyte ratio (NLR)
-
An artificial intelligence-driven predictive model for pediatric allogeneic hematopoietic stem cell transplantation using clinical variables Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-09 Carlos Echecopar, Inés Abad, Víctor Galán-Gómez, Yasmina Mozo del Castillo, Luisa Sisinni, David Bueno, Beatriz Ruz, Antonio Pérez-Martínez
Hematopoietic stem cell transplantation (HSCT) is a procedure with high morbidity and mortality. Identifying patients for maximum benefit and risk assessment is crucial in the decision-making process. This has led to the development of predictive risk models for HSCT in adults, which have limitations when applied to pediatric population. Our goal was to develop an automatic learning algorithm to predict
-
Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-05 Nadine Kutsch, Philipp Gödel, Conrad-Amadeus Voltin, Michael Hallek, Christof Scheid, Peter Borchmann, Udo Holtick
Patients with Richter's transformation of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL-RT) face a dismal prognosis. A 51-year-old female patient diagnosed with CLL with deletion (17p) in 2009. CLL treatment included chemoimmunotherapy and targeted substances. DLBCL-RT was diagnosed in November 2016. After receiving an allogeneic hematopoietic stem cell transplantation
-
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-04 Sibylle C. Mellinghoff, Sandra Robrecht, Rosanne Sprute, Leonie Mayer, Leonie M. Weskamm, Christine Dahlke, Henning Gruell, Finn Teipel, Hans A. Schlößer, Klara Siepmann, Martin Thelen, Anna-Maria Fink, Kirsten Fischer, Florian Klein, Marylyn M. Addo, Androniki Kolovou, Oliver A. Cornely, Barbara Eichhorst, Michael Hallek, Petra Langerbeins
Preventing severe COVID-19 remains a priority globally, particularly in the immunocompromised population. As shown in healthy individuals, immunity against SARS-CoV-2 can be yielded by previous infection, vaccination, or both (hybrid immunity). The objective of this observation study was to investigate hybrid immunity in patients with chronic lymphocytic leukemia (CLL).
-
Disseminated intravascular coagulation score evolution in 48 h predicts early death in acute promyelocytic leukemia patients Eur. J. Haematol. (IF 3.1) Pub Date : 2024-02-02 Joana Brioso Infante, Graça Vasconcelos Esteves, João Raposo, João Forjaz de Lacerda
Early death (ED) is the unsolved issue of acute promyelocytic leukemia (APL). The disseminated intravascular coagulation (DIC) score has been proposed as a marker of bleeding and death in APL; whether its temporal evolution predicts outcomes in APL is unknown. We evaluated whether an increasing score 48 h after diagnosis associates with ED.
-
Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-31 Martin H. J. Wiesen, Jannik Stemler, Cornelia Fietz, Carolin Joisten, Oliver A. Cornely, Nick Verougstraete, Thomas Streichert, Carsten Müller
Midostaurin is an oral multitargeted tyrosine kinase inhibitor for the treatment of acute myeloid leukemia (AML). Therapeutic drug monitoring of midostaurin may support its safe use when suspecting toxicity or combined with strong CYP3A4 inhibitors.
-
The applicability of the central line-associated bloodstream infection (CLABSI) criteria for the evaluation of bacteremia episodes in pediatric oncology patients Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-31 Ceder H. van den Bosch, Florine N. J. Frakking, Yvette G. T. Loeffen, Harm van Tinteren, Alida F. W. van der Steeg, Marc H. W. A. Wijnen, Marianne D. van de Wetering, Jan-Tom van der Bruggen
The aim of this study was to investigate the applicability of the central line-associated bloodstream infection (CLABSI) criteria of the Centers for Disease Control and Prevention in pediatric oncology patients.
-
Late transplant-associated thrombotic microangiopathy verified in bone marrow biopsy specimens is associated with chronic GVHD and viral infections Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-20 Wolfgang Hill, Karl Sotlar, Anke Hautmann, Hans-Jochem Kolb, Johanna Ullmann, Andreas Hausmann, Michael Schmidt, Johanna Tischer, Thu-Trang Pham, Andreas Rank, Manuela A. Hoechstetter
To describe late transplant-associated thrombotic microangiopathy (TA-TMA) as chronic endothelial complication in bone marrow (BM) after allogeneic hematopoietic stem cell transplantation (HSCT).
-
JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-16 Christina Schjellerup Eickhardt-Dalbøge, Henrik V. Nielsen, Kurt Fuursted, Christen Rune Stensvold, Lee O' Brien Andersen, Berit Lilje, Morten Kranker Larsen, Lasse Kjær, Sarah Friis Christensen, Trine Alma Knudsen, Vibe Skov, Anders Lindholm Sørensen, Christina Ellervik, Lars Rønn Olsen, Jens Jørgen Elmer Christensen, Xiaohui Chen Nielsen, Hans Carl Hasselbalch, Anna Cäcilia Ingham
Essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady-state hematopoiesis.
-
Pattern of use and clinical outcomes with rIX-FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real-world study Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-15 Paola Giordano, Berardino Pollio, Gianluca Sottilotta, Chiara Biasoli, Filomena Daniele, Raimondo De Cristofaro, Flora Peyvandi, Maria Rosaria Villa, Giancarlo Castaman
To evaluate pattern of use and clinical outcomes in pediatric/adolescent patients enrolled in the IDEAL study.
-
Comparison of telomere length in patients with bone marrow failure syndromes and healthy controls Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-12 Aruna Barade, Kavitha M. Lakshmi, Anu Korula, Fouzia N. Abubacker, Uday P. Kulkarni, Aby Abraham, Vikram Mathews, Biju George, Eunice S. Edison
During normal aging, telomeric DNA is gradually lost in dividing somatic cells, and critically short telomeres lead to replicative senescence, apoptosis, or chromosomal instability. We studied telomere length in bone marrow failure syndromes (BMFS) compared to normal healthy population.
-
Soluble mannose receptor: A potential biomarker in Gaucher disease Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-10 Brendan Beaton, Derralynn A. Hughes
Soluble mannose receptor (sMR) relates to mannose receptor expression on macrophages, and is elevated in inflammatory disorders. Gaucher disease (GD) has altered macrophage function and utilises mannose receptors for enzyme replacement therapy (ERT) endocytosis. sMR has not previously been studied in GD.
-
Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-10 Jonas Kassow Gronlund, Christopher Veigaard, Caroline Juhl-Christensen, Anne-Sofie Skou, Dorte Melsvik, Hans Beier Ommen
Follow-up after allogeneic transplantation in acute myeloid leukaemia (AML) is guided by measurable residual disease (MRD) testing. Quantitative polymerase chain reaction (qPCR) is the preferred MRD platform but unfortunately, 40%–60% of AML patients have no high-quality qPCR target. This study aimed to improve MRD testing by utilising droplet digital PCR (ddPCR). ddPCR offers patient-specific monitoring
-
A post hoc analysis of PROTECT VIII kids assessing long-term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-09 Sanjay Ahuja, Tina Biss, Monika Maas Enriquez, Maria Elisa Mancuso, MacGregor Steele, Gili Kenet
The safety and efficacy of the extended half-life factor VIII (FVIII) product damoctocog alfa pegol (BAY 94-9027, Jivi®) has been demonstrated in the PROTECT VIII Kids study (NCT01775618), where male previously-treated patients (PTPs) aged <12 years old with severe haemophilia A and ≥ 50 exposure days (EDs) were treated prophylactically. The PROTECT VIII Kids extension study assessed the long-term
-
Transcriptome analysis of primary adult B-cell lineage acute lymphoblastic leukemia identifies pathogenic variants and gene fusions, and predicts subtypes for in depth molecular diagnosis Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-08 Mirjam Podgorica, Elsa Drivet, Jonas Krag Viken, Alyssa Richman, Johanne Vestbøstad, Peter Szodoray, Ann Kristin Kvam, Hilde Skuterud Wik, Geir E. Tjønnfjord, Ludvig A. Munthe, Seth Frietze, Hilde Schjerven
B-cell acute lymphoblastic leukemia (B-ALL) is classified into subgroups based on known driver oncogenes and molecular lesions, including translocations and recurrent mutations. However, the current diagnostic tests do not identify subtypes or oncogenic lesions for all B-ALL samples, creating a heterogeneous B-ALL group of unknown subtypes.
-
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir-exposed CMV-free population receiving PTCy Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-06 Eugenio Galli, Elisabetta Metafuni, Carlo Gandi, Maria Assunta Limongiello, Sabrina Giammarco, Andrea Mattozzi, Rosaria Santangelo, Andrea Bacigalupo, Federica Sorà, Patrizia Chiusolo, Simona Sica
Hemorrhagic cystitis (HC) is a highly impacting complication in allogeneic hematopoietic stem cell transplantation (HSCT), occurring in 12%–37% of patients. The impact of transplant- and patient-specific variables has been described, with a possible role for JCV and BKV, which may be cooperating with cytomegalovirus (CMV). Here, we analyze 134 letermovir-exposed, CMV-free patients, treated with the
-
Trends in underlying causes of death in allogeneic hematopoietic cell transplant recipients over the last decade Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-06 Andreas Søborg, Joanne Reekie, Henrik Sengeløv, Caspar Da Cunha-Bang, Thomas Kromann Lund, Christina Ekenberg, Isabelle Paula Lodding, Kasper Sommerlund Moestrup, Louise Lundgren, Jens D. Lundgren, Neval Ete Wareham
Improved survival after hematopoietic cell transplantation (HCT) and an increasingly comorbid transplant population may give rise to new trends in the causes of death.
-
Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-03 Nobuhiko Yamauchi, Dai Maruyama
Chimeric antigen receptor (CAR) T-cell therapy has become a commercially available treatment option for relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) with two or more lines of prior therapies, and recently for high-risk r/r DLBCL with one prior line of therapy. The successful development of CAR T-cell therapy for multiple relapsed DLBCL has led to a boom in subsequent trials that
-
Feasibility, accuracy, and usability analysis of MapAML, a first-in-class app for integrated diagnosis in acute myeloid leukemia Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-03 Thaís B. Moyen, Victoria Tomaz, Paulo V. Campregher
Performing a comprehensive diagnosis of acute myeloid leukemia (AML) is complex and involves the integration of clinical information, bone marrow morphology, immunophenotyping, cytogenetic, and molecular analysis, which can be challenging to the general hematologist. The aim of this study was to evaluate the usability and accuracy of MapAML, a smartphone app for integrated diagnosis in AML, created
-
Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients Eur. J. Haematol. (IF 3.1) Pub Date : 2024-01-02 Vanja Zeremski, Louisa Adolph, Sina Beer, Mirjeta Berisha, Benedikt Jacobs, Christoph Kahl, Christian Koenecke, Siegfried Kropf, Jens Panse, Judith Petersen, Martin Schmidt-Hieber, Jessica Schneider, Vladan Vucinic, Jeanette Walter, Oliver Weigert, Hanno M. Witte, Dimitrios Mougiakakos
Treatment intensification (including consolidative high-dose chemotherapy with autologous stem cell transplantation [HDT-ASCT]) significantly improved outcome in primary central nervous system lymphoma (PCNSL) patients.
-
Effects of tertiary palliative care on the pattern of end-of-life care in patients with hematologic malignancies in Korea Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-28 Dong Hyun Kim, Jeonghwan Youk, Ja Min Byun, Youngil Koh, Junshik Hong, Tae Min Kim, Inho Kim, Sung-Soo Yoon, Shin Hye Yoo, Dong-Yeop Shin
Patients with hematologic malignancies (HMs) often face challenges in accessing palliative care (PC) and receiving quality end-of-life (EOL) care. We examined factors associated with referrals to tertiary PC and the effects of tertiary PC on EOL care in patients with HMs.
-
Delayed diagnostic interval and survival outcomes in pediatric leukemia: A single-center, retrospective study Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-28 Kosuke Tamefusa, Motoharu Ochi, Hisashi Ishida, Takahiro Shiwaku, Kiichiro Kanamitsu, Kaori Fujiwara, Yasuhisa Tatebe, Naomi Matsumoto, Kana Washio, Hirokazu Tsukahara
This study primarily focused on the diagnostic interval (DI), defined as the duration from the onset of leukemic symptoms to diagnosis. We investigated whether a prolonged DI is associated with the outcomes of pediatric leukemia.
-
Outcomes in Kaposi's sarcoma-associated herpesvirus -associated primary effusion lymphoma and multicentric Castleman's disease in patients with human immunodeficiency virus (HIV) in a safety-net hospital system Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-28 Melanie Lopez, Radhika Kainthla, Susana Lazarte, Weina Chen, Ank E. Nijhawan, Sheena Knights
To describe cases of Kaposi's sarcoma-associated herpesvirus (KSHV)-associated multicentric Castleman's disease (MCD) and primary effusion lymphoma (PEL) in patients with HIV from a large, safety-net hospital system in Dallas, Texas, USA.
-
Enhancing thalassemia gene carrier identification in non-anemic populations using artificial intelligence erythrocyte morphology analysis and machine learning Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-28 Fan Zhang, Jieyu Zhan, Yang Wang, Jing Cheng, Meinan Wang, Peisong Chen, Juan Ouyang, Junxun Li
Non-anemic thalassemia trait (TT) accounted for a high proportion of TT cases in South China.
-
Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-25 Moritz Lehne, K. Martin Kortüm, Karthik Ramasamy, Elena Zamagni, Tim d'Estrubé, Evi Zhuleku, Maya Hanna, Soham Shukla, Marco Ghiani, Ulf Maywald, Thomas Wilke, Lenka Kellermann, Sue Perera
To retrospectively analyze real-world treatment patterns in patients with relapsed/refractory multiple myeloma (RRMM) who initiated third-line treatment in Europe.
-
Use of platelet transfusions and tranexamic acid in patients with myelodysplastic syndromes: A clinical practice survey Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-20 Allison Mo, Robert Weinkove, Erica M. Wood, Jake Shortt, Anna Johnston, Zoe K. McQuilten
Thrombocytopenia and bleeding are common in myelodysplastic syndromes (MDS), but optimal management is unknown. We conducted a survey to identify current clinical practice regarding platelet transfusion (PLT-T) and tranexamic acid (TXA) to inform future trial design.
-
Screening for multidrug-resistant organisms in high-risk hospitalized patients with hematologic diseases Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-20 Valentine Delanote, Rutger Callens, Dirk Vogelaers, Dries Deeren
Patients treated for hematologic malignancies are at higher risk for blood stream infections (BSI) and multidrug-resistant organisms (MDRO) are increasingly involved. Studies showed a significant association between rectal colonization status and a higher risk of subsequent MDRO BSI. The objective of our study was to probe the practice of surveillance cultures in Belgian hematology centers.
-
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-20 Clement Twumasi, Sally Moore, Ross Sadler, Sally Jeans, Sherin Varghese, Alison Turner, Gaurav Agarwal, Jemma Larham, Nathanael Gray, Oluremi Carty, Joe Barrett, Stella Bowcock, Udo Oppermann, Vicky Gamble, Gordon Cook, Chara Kyriakou, Mark Drayson, Supratik Basu, Sarah McDonald, Shelagh McKinley, Sarah Gooding, Muhammad K. Javaid, Karthik Ramasamy
To describe determinants of persisting humoral and cellular immune response to the second COVID-19 vaccination among patients with myeloma.
-
Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-17 Supriya Gupta, Mira Kohorst, Hassan B. Alkhateeb
Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive B-cell neoplasm associated with poor outcomes. Conventional multiagent chemotherapy and bispecific antibody therapy may induce remission; however, relapse rates remain high and overall survival is poor. Chimeric antigen receptor T-cell (CAR-T) therapy provides durable, deep complete remission, and long-term cures in
-
Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial Eur. J. Haematol. (IF 3.1) Pub Date : 2023-12-19 Tetsuya Mori, Tomoo Osumi, Akiko Kada, Kentaro Ohki, Yuhki Koga, Reiji Fukano, Naoto Fujita, Tetsuo Mitsui, Takeshi Mori, Akiko M. Saito, Atsuko Nakazawa, Ryoji Kobayashi, Masahiro Sekimizu
The benefit of adding rituximab to standard lymphomes malins B (LMB) chemotherapy for children with high-risk mature B-cell non-Hodgkin lymphoma (B-NHL) has previously been demonstrated in an international randomized phase III trial, to which the Japanese Pediatric Leukemia/Lymphoma Study Group could not participate.